NKGen Biotech
NKGN · OTC · United States
Share price · NKGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NKGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Aug 2026-50.0%
Nothing announced by NKGN that day or the session before.
- 31 Jul 2026-83.3%
Nothing announced by NKGN that day or the session before.
- 16 Jun 2026-60.0%
Nothing announced by NKGN that day or the session before.
- 15 Jun 2026+150.0%
Nothing announced by NKGN that day or the session before.
- 17 Mar 2026+216.7%
Nothing announced by NKGN that day or the session before.
- 5 Mar 2026+185.7%
Nothing announced by NKGN that day or the session before.
- 18 Feb 2026-65.0%
Nothing announced by NKGN that day or the session before.
- 17 Feb 2026+233.3%
Nothing announced by NKGN that day or the session before.
- 14 Oct 2025+900.0%
Nothing announced by NKGN that day or the session before.
- 10 Oct 2025+100.0%
Share of unusual movement by asset
For each asset, the share of NKGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 2% |
| Sessions with no dated event | — | 98% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | NK cell therapyCell therapy | Alzheimer's DiseaseNon-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | — | $1.9M | <$0.1M | —-$2.8M operating cash flow | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q3 | — | $2.8M | $0.2M | —-$3.9M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.1M | $0.3M | $16M-$6.0M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.2M | $0.3M | $5.4M-$4.0M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $3.9M | $9.0M | $33M-$14M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.0M | <$0.1M | $1.8M-$0.6M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.6M | $0.2M | —-$0.5M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $4.1M | $0.7M | —-$0.5M operating cash flow | report ↗ |
| 2022-Q2 | — | — | $1.3M | —-$0.2M operating cash flow | report ↗ |
| 2022-Q1 | — | — | $1.4M | —-$0.3M operating cash flow | report ↗ |
| 2021-Q3 | — | — | $1.9M | —-$0.1M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $11M | $0.2M | $11M-$21M operating cash flow | report ↗ |
NKGen Biotech reported R&D spend of $10.66M, down 32.0% YoY, cash and equivalents of $0.24M, and a net loss of $44.29M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text
Insider transactions
Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1 reporting institution held 2.8M shares ($193K, 2.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | METEORA CAPITAL, LLC | 2,755,935 | $193K |